Approaching Gold‐Standard Sensitivity in a Portable and Versatile Gold Nanoprisms Thermoplasmonic Platform for Lateral Flow Detection of Biomolecules
Source abstract
Abstract
ABSTRACT Plasmonic nanoparticles exhibit unique optical and thermal properties that make them ideal for next‐generation diagnostic technologies. Among them, gold nanoprisms (AuNPrs) are especially powerful due to their anisotropic geometry, tunable surface plasmon resonance in the near‐infrared (NIR) region, and high photothermal conversion efficiency. These features transform them from passive labels into active nanotransducers capable of amplifying diagnostic signals. Building on these advantages, we developed two AuNPr‐based sensing platforms: Thermo Lateral Flow Immunoassay (ThermoLFIA) and Thermo Oligonucleotide‐based Lateral Flow Assay (ThermoOLFA). By coupling AuNPrs with thermoresponsive substrates, both systems use localized heat generation to boost analytical sensitivity, enabling visual enhancement far beyond that of conventional gold spheres. ThermoLFIA demonstrated clinically relevant detection of gastrointestinal cancer biomarkers (CEA, CA19‐9, VEGF), outperforming standard ELISA tests. In parallel, functionalization of AuNPrs with DNA probes enabled ThermoOLFA to detect SARS‐CoV‐2 RNA with sensitivity comparable to RT‐qPCR, but without amplification steps and within 25 min. This proof‐of‐concept confirms that plasmonic nanoprisms can drive rapid, portable, and ultrasensitive diagnostics, opening a path toward point‐of‐care platforms with strong clinical and translational potential.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Gold and Silver Nanoparticles Synthesis and Applications · Biosensors and Analytical Detection · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Instituto de Nanociencia y Materiales De Aragón (INMA) Consejo Superior de Investigaciones Científicas (CSIC) University of Zaragoza Zaragoza Spain
Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER‐BBN) Instituto De Salud Carlos III Madrid Spain
Funding
Fundació la Marató de TV3 · Consejo Superior de Investigaciones Científicas · Agencia Estatal de Investigación
References (51)
Show source-provided references
1. 10.1177/2150132721104778210.1177/21501327211047782 ↗
2. 10.3389/fnano.2024.146542910.3389/fnano.2024.1465429 ↗
3. 10.1038/nprot.2006.5110.1038/nprot.2006.51 ↗
4. DiaSorin VERIGENE® System Overview accessed2024 https://int.diasorin.com/en/molecular‐diagnostics/tools/verigene‐system.
5. 10.1080/14737159.2024.233077410.1080/14737159.2024.2330774 ↗
6. 10.1016/S1473‐3099(21)00048‐710.1016/S1473‐3099(21)00048‐7 ↗
7. 10.1042/EBC2015001210.1042/EBC20150012 ↗
8. 10.1021/acsnano.0c1003510.1021/acsnano.0c10035 ↗
9. 10.1002/anie.20120099710.1002/anie.201200997 ↗
10. 10.1039/D3NR01858J10.1039/D3NR01858J ↗
11. 10.2147/IJN.S21883410.2147/IJN.S218834 ↗
12. 10.1016/j.bios.2018.09.03910.1016/j.bios.2018.09.039 ↗
13. 10.1039/C3CC39112D10.1039/C3CC39112D ↗
14. 10.3390/ijms23231525810.3390/ijms232315258 ↗
15. 10.1016/j.ijbiomac.2024.13054010.1016/j.ijbiomac.2024.130540 ↗
16. 10.1021/acsomega.5c0215510.1021/acsomega.5c02155 ↗
17. 10.3748/wjg.v29.i17.251510.3748/wjg.v29.i17.2515 ↗
18. 10.1126/science.aay904010.1126/science.aay9040 ↗
19. Abcam CEA Human ELISA Kit (ab99992) 2023 https://www.abcam.com.
20. R&D Systems Human VEGF Quantikine® ELISA Kit 2023 https://www.rndsystems.com.
21. BioVision CA 19‐9 (Human) ELISA Kit 2023 https://www.biovision.com.
22. 10.2217/nnm‐2016‐025710.2217/nnm‐2016‐0257 ↗
23. 10.1186/s11671‐019‐3240‐310.1186/s11671‐019‐3240‐3 ↗
24. 10.1021/la204712u10.1021/la204712u ↗
25. 10.1021/nn200019s10.1021/nn200019s ↗
26. 10.1021/acsami.0c0202210.1021/acsami.0c02022 ↗
27. 10.1002/smll.20190496010.1002/smll.201904960 ↗
28. 10.1021/acsanm.3c0305310.1021/acsanm.3c03053 ↗
29. 10.1039/D4AY00381K10.1039/D4AY00381K ↗
30. 10.1007/s00604‐017‐2464‐010.1007/s00604‐017‐2464‐0 ↗
31. 10.1016/j.cjac.2025.10058010.1016/j.cjac.2025.100580 ↗
32. 10.1038/s41551‐020‐00655‐z10.1038/s41551‐020‐00655‐z ↗
33. 10.3390/bioengineering802002310.3390/bioengineering8020023 ↗
34. 10.1002/btm2.1030510.1002/btm2.10305 ↗
35. 10.1039/d4ay01010h10.1039/d4ay01010h ↗
36. 10.1038/s41467‐025‐58663‐z10.1038/s41467‐025‐58663‐z ↗
37. 10.3390/v1706078310.3390/v17060783 ↗
38. 10.1128/spectrum.01207‐2310.1128/spectrum.01207‐23 ↗
39. 10.3390/v1506125410.3390/v15061254 ↗
40. 10.1038/s41598‐024‐62249‐y10.1038/s41598‐024‐62249‐y ↗
41. 10.1128/JCM.02880-2010.1128/JCM.02880-20 ↗
42. 10.1371/journal.pone.026086210.1371/journal.pone.0260862 ↗
43. 10.1056/NEJMc202617210.1056/NEJMc2026172 ↗
44. 10.1002/anie.20201450610.1002/anie.202014506 ↗
45. 10.1007/s10529‐022‐03316‐010.1007/s10529‐022‐03316‐0 ↗
46. 10.1126/science.aam932110.1126/science.aam9321 ↗
47. 10.1371/journal.pbio.004020410.1371/journal.pbio.0040204 ↗
48. 10.1093/nar/28.12.e6310.1093/nar/28.12.e63 ↗
49. 10.1038/s41587‐021‐00966‐910.1038/s41587‐021‐00966‐9 ↗
50. ICH Validation of Analytical Procedures Q2(R2) 2023 https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf.
51. 10.1351/pac19976902029710.1351/pac199769020297 ↗